Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study

Tumori

Volumn 100, Issue 2, 2014, Pages 143-148

  Artac, Mehmet ^a   Turhal, Nazim Serdar ^b   Kocer, Murat ^c   Karabulut, Bulent ^d   Bozcuk, Hakan ^e   Yalcin, Suayip ^f   Karaagac, Mustafa ^a   Gündüz, Seyda ^e   Isik, Nalan ^f   Uygun, Kazim ^g  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^e AKDENIZ UNIVERSITY   (Turkey)

^f HACETTEPE UNIVERSITY   (Turkey)

^g KOCAELI UNIVERSITY   (Turkey)

Author keywords

Adjuvant therapy; Colon cancer; Prognostic factors

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; PERINEURAL INVASION; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; TURKEY (REPUBLIC);

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLECTOMY; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INTESTINAL OBSTRUCTION; INTESTINAL PERFORATION; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TURKEY;

EID: 84901387956     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161410000205     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127: 2893-2917, 2010.
2. Aykan N, Demir G, Disci R, Yalcin S, Turhal NS, Ozdogan M, Ozkan M, Yaren A, Camci C, Akbulut H: Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: a cross-sectional disease registry study-A Turkish Oncology Group trial. J Clin Oncol, 29 (Suppl 4): abstr 394, 2011.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds): American Joint Committee on Cancer Staging Manual, 7th ed, Springer, New York, 2009.
4. Surveillance Epidemiology and End Results (SEER). Available from http://seer.cancer.gov/statistics/
5. de Gramont A, de Gramont A, Chibaudel B, Larsen AK, Tournigand C, André T; GERGOR French Oncology Research Group: The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer, 10: 218-226, 2011.
6. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med, 319: 525-532, 1988.
7. Roth AD, Tejpar S, Yan P, Fiocca R, Dietrich D, Delorenzi M, Labianca R, Cunningham D, Van Cutsem E, Bosman F: Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC3 - EORTC40993-SAKK60-00 trial. J Clin Oncol, 27 (Suppl 15): abstr 4002, 2009.
8. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. N Engl J Med, 350: 2343-2351, 2004.
9. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon: results from NSABP C-07. J Clin Oncol, 25: 2198-2204, 2007. (Pubitemid 46954643)
10. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ; Quasar Collaborative Group: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370: 2020-2029, 2007.
11. Tournigard C, de Gramont A: Chemotherapy: is adjuvant chemotherapy an option for stage II colon cancer? Nat Rev Clin Oncol, 8: 574-576, 2011.
12. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 124: 979-994, 2000. (Pubitemid 30602039)
13. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 22: 3408-3419, 2004. (Pubitemid 41103700)
14. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer.
15. O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA: Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol, 29: 3381-3388, 2011.
16. Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, Labianca R, Shi Q, Bleyer A, de Gramont A, Sargent D: Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol, 30: 2334-2339, 2012.
17. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folonic acid in B2 colon cancer. J Clin Oncol, 17: 1356-1363, 1999.
18. Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, Grönberg H, Hultborn R, Albertsson M, Påhlman L, Tveit KM: Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol, 44: 904-912, 2005. (Pubitemid 41780118)
19. Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM: Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol, 27: 4109-4115, 2009.
20. Jee SH, Moon SM, Shin US, Yang HM, Hwang DY: Effectiveness of adjuvant chemotherapy with 5-FU/leucovorin and prognosis in stage II colon cancer. J Korean Soc Coloproctol, 27: 322-328, 2011.
21. Hashiguchi Y, Hase K, Ueno H, Shinto E, Naito Y, Kajiwara Y, Kuroda T, Yamamoto J, Mochizuki H: Impact of race/ethnicity on prognosis in patients who underwent surgery for colon cancer: analysis for White, African, and East Asian Americans. Ann Surg Oncol, 19: 1517-1528, 2012.
22. Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW; ACCENT Collaborative Group: Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst, 103: 1498-1506, 2011.
23. Wu X, Zhang J, He X, Wang C, Lian L, Liu H, Wang J, Lan P: Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg, 16: 646-655, 2012.
24. Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P: Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol, 22: 484-492, 2004. (Pubitemid 41079778)
25. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA: Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst, 99: 433-441, 2007. (Pubitemid 47073566)
26. Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, Chen CW, Wang JY: Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol, 100: 736-743, 2009.
27. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 27: 3109-3116, 2009.
28. Yothers GA, Allegra CJ, O'Connell MJ, George TJ, Sharif S, Petrelli NJ, Lopa S, Wolmark N: The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. J Clin Oncol, 29 (Suppl): abstr 3507, 2011.
29. Tournigard C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A: Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analysis of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol, 30: 3353-3360, 2012.
30. Sato H, Maeda K, Sugihara K, Mochizuki H, Kotake K, Teramoto T, Kameoka S, Saito Y, Takahashi K, Hirai T, Ohue M, Shirouzu K, Sakai Y, Watanabe T, Hirata K, Hatekeyama K: High-risk stage II colon cancer after curative resection. J Surg Oncol, 104: 45-52, 2011.